Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Faculty Members have conducted research related to the Covid-19 Among Patients With Multiple Sclerosis a Systematic Review
Mohammad Ali Sahraian
Mohammad Ali Sahraian

Professor of Multiple Sclerosis and Related Disorders

Department Neurology

School of Medicine

Sina Hospital

Multiple Sclerosis Research Center

Tehran University of Medical Sciences

Related Documents
1. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)
2. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
3. Evaluation of the Rate of Covid-19 Infection, Hospitalization and Death Among Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)
4. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
5. Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection, Multiple Sclerosis and Related Disorders (2022)
6. Implementing Coronavirus Disease 2019 Scale-Up Registry Protocol in National Multiple Sclerosis Registry System of Iran, Current Journal of Neurology (2021)
7. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
8. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
9. The Study of Covid-19 Infection Following Vaccination in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
10. Assessment of Covid-19 Vaccine Attitude in People With Multiple Sclerosis, Its Correlation With Demographic Factors, and Fear of Coronavirus: A Cross-Sectional Survey, Current Journal of Neurology (2022)
All Documents
1. Computerized Cognitive Rehabilitation in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Caspian Journal of Internal Medicine (2025)
2. Investigating Treatment Alternatives for Fingolimod in Patients With Multiple Sclerosis Developed Refractory Fingolimod-Related Genital Human Papilloma Virus (Hpv) Infection, Multiple Sclerosis and Related Disorders (2025)
3. A National Registry-Based Study of Ethnic Differences in People With Multiple Sclerosis in Iran, Clinical Neurology and Neurosurgery (2024)
4. A National Registry-Based Study of Ethnic Differences in People With Multiple Sclerosis in Iran, Clinical Neurology and Neurosurgery (2024)
5. Choosing the Best Instrument for Measuring Health Spillover Effect in Caregivers of Patients With Multiple Sclerosis, Value in Health Regional Issues (2024)
6. Comparing Infusion-Related Reactions of the First Full Dose (600 Mg) Biosimilar Ocrelizumab Administration With the Standard Divided Protocol in Multiple Sclerosis Patients: A Randomized Controlled Trial Study, Acta Neurologica Belgica (2024)
7. Consanguineous Marriage Among Familial Multiple Sclerosis Subjects: A National Registry-Based Study, Heliyon (2024)
8. Consensus Recommendations for Diagnosis and Treatment of Multiple Sclerosis: 2023 Revision of the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2024)
9. Disease-Modifying Therapies, Outcomes, Risk Factors and Severity of Covid-19 in Multiple Sclerosis: A Menactrims Registry Based Study, Multiple Sclerosis and Related Disorders (2024)
10. Effect of Ginseng on Fatigue Related to Neuromyelitis Optica Spectrum Disorder: A Double-Blinded Randomized Controlled Clinical Trial, Caspian Journal of Internal Medicine (2024)
11. Evaluating Efficacy and Safety of Ocrelizumab Biosimilar (Xacrel) Compared to the Originator (Ocrevus) in Relapsing Multiple Sclerosis: A Phase Iii, Randomized, Equivalency, Clinical Trial, Scientific Reports (2024)
12. Global Age-Sex-Specific Mortality, Life Expectancy, and Population Estimates in 204 Countries and Territories and 811 Subnational Locations, 1950–2021, and the Impact of the Covid-19 Pandemic: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2021, The Lancet (2024)
13. Global Estimates on the Number of People Blind or Visually Impaired by Cataract: A Meta-Analysis From 2000 to 2020, Eye (Basingstoke) (2024)
14. Global Estimates on the Number of People Blind or Visually Impaired by Uncorrected Refractive Error: A Meta-Analysis From 2000 to 2020, Eye (Basingstoke) (2024)
15. Global, Regional, and National Burden of Disorders Affecting the Nervous System, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021, The Lancet Neurology (2024)
16. Global, Regional, and National Burden of Disorders Affecting the Nervous System, 1990–2021: A Systematic Analysis for the Global Burden of Disease Study 2021, The Lancet Neurology (2024)
17. Good Manufacturing Practices Production of Human Placental Derived Mesenchymal Stem Cells for Therapeutic Applications: Focus on Multiple Sclerosis, Molecular Biology Reports (2024)
18. Investigating the Effects of 25-Hydroxyvitamin D3 on Clinical Outcomes in Multiple Sclerosis Patients: A Randomized, Double-Blind Clinical Trial- a Pilot Study, Multiple Sclerosis and Related Disorders (2024)
19. Investigation of Pregnancy Tendency, Reproductive Characteristics, and Disability in Women With Multiple Sclerosis: A Secondary Data Analysis of the National Registry in Iran, Current Journal of Neurology (2024)
20. Neuromyelitis Optica Spectrum Disorders Registry System in Iran: Validity of Data Sets, Multiple Sclerosis and Related Disorders (2024)
21. Presence of Palinopsia As a Sign of Selective Cns Tractopathy: A Case Report; [Presencia De Palinopsia Como Signo De Tractopatia Selectiva Del Snc: Reporte De Un Caso], Revista Cientifica de la Sociedad Espanola de Enfermeria Neurologica (2024)
22. Protocol of a Prospective Multicenter Study on Comorbidity Impact on Multiple Sclerosis and Antibody-Mediated Diseases of the Central Nervous System (Commit), Frontiers in Immunology (2024)
23. Publisher Correction: Global Estimates on the Number of People Blind or Visually Impaired by Cataract: A Meta-Analysis From 2000 to 2020 (Eye, (2024), 38, 11, (2156-2172), 10.1038/S41433-024-02961-1), Eye (Basingstoke) (2024)
24. T1 Hypointense Brain Lesions in Nmosd and Its Relevance With Disability: A Single Institution Cross-Sectional Study, BMC Neurology (2024)
25. The Effect of Crocin-Selenium Nanoparticles on the Cognition and Oxidative Stress Markers of Multiple Sclerosis Patients: A Randomized Triple-Blinded Placebo-Controlled Clinical Trial, BioMetals (2024)
26. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
27. Time Interval Between the Onset of Symptoms and Diagnosis of Multiple Sclerosis and the Influential Factors: A National Registry-Based Study, Clinical Neurology and Neurosurgery (2024)
28. Adverse Side Effects of Glatiramer Acetate and Interferon Beta-1A in Patients With Multiple Sclerosis: A Systematic Review of Case Reports, Current Journal of Neurology (2023)
29. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
30. Alternate Dosing of Fingolimod in Relapsing-Remitting Multiple Sclerosis: A Systematic Review, Current Journal of Neurology (2023)
31. Association of Body Mass Index and Physical Activity With Fatigue, Depression, and Anxiety Among Iranian Patients With Multiple Sclerosis, Frontiers in Neurology (2023)
32. Associations Between Toxoplasma Gondii Infection and Multiple Sclerosis: A Case-Control Seroprevalence Study, Iranian Journal of Parasitology (2023)
33. Challenges of Patients With Multiple Sclerosis in Receiving Health Care Services in Iran, Current Journal of Neurology (2023)
34. Cognitive Deficits in Multiple Sclerosis: Auditory and Visual Attention and Inhibitory Control, Applied Neuropsychology:Adult (2023)
35. Comparison of Side Effects of the Dose-1 of Astrazeneca and Sinopharm Vaccines in Patients With Multiple Sclerosis in Kermanshah, Iran (2021), Current Journal of Neurology (2023)
36. Current and Future Trends in Multiple Sclerosis Management: Near East Perspective, Multiple Sclerosis and Related Disorders (2023)
37. Disease-Modifying Therapy in Multiple Sclerosis: Evaluation of Patients Satisfaction in Iranian Multiple Sclerosis Population, Caspian Journal of Internal Medicine (2023)
38. Economic and Social Standing of Individuals in Iran Diagnosed With Multiple Sclerosis, Archives of Iranian Medicine (2023)
39. Economic and Social Standing of Individuals in Iran Diagnosed With Multiple Sclerosis, Archives of Iranian Medicine (2023)
40. Effect of an Educational Intervention Based on the Theory of Planned Behavior on Improving Medication Adherence in Patients With Multiple Sclerosis Treated With Injectable Disease-Modifying Drugs: Randomized Controlled Trial, BMC Public Health (2023)
41. Effect of Vitamin a on Recovery From the Acute Phase of Multiple Sclerosis-Related Optic Neuritis, Double-Blind, Randomized, Placebo-Controlled Trial, Caspian Journal of Internal Medicine (2023)
42. Effectiveness and Safety of Switching From Fingolimod and Natalizumab to Rituximab in Patients With Relapsing Remitting Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2023)
43. Epidemiological Parameters of Multiple Sclerosis in Chaharmahal and Bakhtiari Province, Iran, Current Journal of Neurology (2023)
44. Factors Associated With the Number of Months of Delaying in Multiple Sclerosis Diagnosis: Comparison of Count Regression Models, Current Journal of Neurology (2023)
45. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
46. Fear of Re-Infection, Relapse, and Anxiety During Covid-19 Pandemic in Patients With Multiple Sclerosis: A Multi-Center Study, Current Journal of Neurology (2023)
47. Follow-Up of Patients With Multiple Sclerosis After Covid-19 Vaccination With Sinopharm Vaccine, Caspian Journal of Neurological Sciences (2023)
48. Global, Regional, and National Incidence of Six Major Immune-Mediated Inflammatory Diseases: Findings From the Global Burden of Disease Study 2019, eClinicalMedicine (2023)
49. Global, Regional, and National Incidence of Six Major Immune-Mediated Inflammatory Diseases: Findings From the Global Burden of Disease Study 2019, eClinicalMedicine (2023)
50. Investigation of the Safety of Live Attenuated Varicella-Zoster Virus Vaccination in Patients With Relapse-Remitting Multiple Sclerosis Treated With Natalizumab: A Case Series and Review of the Literature, Multiple Sclerosis and Related Disorders (2023)
51. Iranian Specialists’ Approach to Surgery in Patients With Multiple Sclerosis, Current Journal of Neurology (2023)
52. Iranian Specialists’ Approach to Surgery in Patients With Multiple Sclerosis, Current Journal of Neurology (2023)
53. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)
54. Iranian Specialists’ Approach to Treatment Escalation in Multiple Sclerosis Patients With Cognitive Impairment, Current Journal of Neurology (2023)
55. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
56. Late-Onset Multiple Sclerosis in Iran: A Report on Demographic and Disease Characteristics, Multiple Sclerosis and Related Disorders (2023)
57. Prevalence of Comorbidities in Patients With Multiple Sclerosis Using Administrative Data From 2007 to 2016 in Iran, Multiple Sclerosis and Related Disorders (2023)
58. Psychometric Properties of the Persian Version of Emotions and Attitudes Towards Mri (Mri-Ema), Caspian Journal of Internal Medicine (2023)
59. Safety and Discontinuation Rate of Dimethyl Fumarate (Zadiva®) in Patients With Multiple Sclerosis: An Observational Retrospective Study, Journal of Clinical Medicine (2023)
60. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
61. Safety and Effectiveness of Cinnomer® on Disease Characteristics, Depression, and Quality of Life of Patients With Multiple Sclerosis: A Phase Iv, Post-Marketing, Prospective, Multicenter Study, Archives of Iranian Medicine (2023)
62. Side Effects of First and Second Doses of Inactivated Covid-19 Vaccine in Multiple Sclerosis, Caspian Journal of Neurological Sciences (2023)
63. The Effect of Body Mass Index on the Morbidity and Outcomes of Covid-19 in Iranian Patients With Multiple Sclerosis, Current Journal of Neurology (2023)
64. The Effects of Different Types of Smoking on Recovery From Attack in Hospitalized Multiple Sclerosis Patients, Clinical Neurology and Neurosurgery (2023)
65. The Incidence and Prevalence of Crude and Familial Multiple Sclerosis in Tehran, Iran in 2021, Neurological Sciences (2023)
66. The National Multiple Sclerosis Registry System of Iran (Nmsri): Aspects and Methodological Dimensions, Multiple Sclerosis and Related Disorders (2023)
67. The Prevalence of Cancer in Patients With Multiple Sclerosis (Ms) Who Were Under Treatment With Natalizumab (Tysabri): A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2023)
68. The Prevalence of Multiple Sclerosis in Tehran, Iran, in 2020, Current Journal of Neurology (2023)
69. The Relationship Between Retinal Layer Thickness and Cognition in Patients With Multiple Sclerosis: A Systematic Review of Current Literature, Current Journal of Neurology (2023)
70. The Relationship Between Retinal Layer Thickness and Cognition in Patients With Multiple Sclerosis: A Systematic Review of Current Literature, Current Journal of Neurology (2023)
71. The Relationship Between Social Support and Family Functioning Among Married Multiple Sclerosis Patients in Iran With the Mediating Role of Spiritual Experiences and Moral Foundations, Oman Medical Journal (2023)
72. Therapeutic Plasma Exchange (Tpe) Complications in Patients With Multiple Sclerosis (Ms) and Clinically Isolated Syndrome (Cis): A Report From a Tertiary Center, Neurologist (2023)
73. Vitamins a and D Enhance the Expression of Ror-Γ-Targeting Mirnas in a Mouse Model of Multiple Sclerosis, Molecular Neurobiology (2023)
74. Waterpipe and Cigarette Smoking and Drug and Alcohol Consumption, and the Risk of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Current Journal of Neurology (2023)
75. A Report of Multiple Sclerosis Registry in Mazandaran Province 2019-2021, Journal of Mazandaran University of Medical Sciences (2022)
76. Adding Erythropoietin to Intravenous Methylprednisolone in Acute Treatment of Attacks of Neuromyelitis Optica Spectrum Disorders: A Randomized Controlled Trial, Current Journal of Neurology (2022)
77. Adolescent Transport and Unintentional Injuries: A Systematic Analysis Using the Global Burden of Disease Study 2019, The Lancet Public Health (2022)
78. Adolescent Transport and Unintentional Injuries: A Systematic Analysis Using the Global Burden of Disease Study 2019, The Lancet Public Health (2022)
79. Assessment of Covid-19 Vaccine Attitude in People With Multiple Sclerosis, Its Correlation With Demographic Factors, and Fear of Coronavirus: A Cross-Sectional Survey, Current Journal of Neurology (2022)
80. Association Between Disease-Modifying Therapies and Adverse Clinical Outcomes in Multiple Sclerosis Patients With Covid-19 Infection, Multiple Sclerosis and Related Disorders (2022)
81. Association of Cognitive Impairment and Quality of Life in Patients With Multiple Sclerosis: A Cross-Sectional Study, Current Journal of Neurology (2022)
82. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
83. Characteristics of Covid-19 in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
84. Clinical Characteristics, Radiological Features and Prognostic Factors of Transverse Myelitis Following Covid-19 Vaccination: A Systematic Review, Multiple Sclerosis and Related Disorders (2022)
85. Complementary and Alternative Therapies in Multiple Sclerosis: A Systematic Literature Classification and Analysis, Acta Neurologica Belgica (2022)
86. Covid-19 Vaccine Hesitancy in Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
87. Depression, Anxiety, and Fear of Covid-19 in Patients With Multiple Sclerosis in Pandemic Era: A Cross-Sectional Study, Neurological Sciences (2022)
88. Determining the Effect of Sun Exposure and Physical Activity on the Incidence of Primary Progressive Multiple Sclerosis, Tehran University Medical Journal (2022)
89. Disease-Modifying Therapies and T1 Hypointense Lesions in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, CNS Neuroscience and Therapeutics (2022)
90. Effect of Eight Weeks Respiratory Muscle Training on Respiratory Capacity, Functional Capacity and Quality of Life on Subjects With Mild to Moderate Relapsing-Remitting Multiple Sclerosis: A Single-Blinded Randomized Controlled Trial, Multiple Sclerosis and Related Disorders (2022)
91. Effect of Endurance Training on Cardiopulmonary Fitness in People With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
92. Effect of Rituximab on the Cognitive Impairment in Patients With Secondary Progressive Multiple Sclerosis, Caspian Journal of Internal Medicine (2022)
93. Epidemiology of Familial Multiple Sclerosis in Iran: A National Registry-Based Study, BMC Neurology (2022)
94. Epidemiology of Familial Multiple Sclerosis in Iran: A National Registry-Based Study, BMC Neurology (2022)
95. Estimates, Trends, and Drivers of the Global Burden of Type 2 Diabetes Attributable to Pm2·5 Air Pollution, 1990–2019: An Analysis of Data From the Global Burden of Disease Study 2019, The Lancet Planetary Health (2022)
96. Estimation of the Global Prevalence of Dementia in 2019 and Forecasted Prevalence in 2050: An Analysis for the Global Burden of Disease Study 2019, The Lancet Public Health (2022)
97. Exploring the Association of Reproductive History With the Development and Course of Neuromyelitis Optica Spectrum Disorder, Clinical Neurology and Neurosurgery (2022)
98. Fatigue in Multiple Sclerosis Is a Diagnostic Challenge: A Cross-Sectional Study, Journal of Research in Clinical Medicine (2022)
99. Global Assessment of Characteristics of Multiple Sclerosis Registries; a Systematic Review, Multiple Sclerosis and Related Disorders (2022)
100. Hotair and Malat1 Long Noncoding Rnas Regulate Bdnf Expression and Oligodendrocyte Precursor Cell Differentiation, Molecular Neurobiology (2022)
101. Increasing Incidence and Male to Female Sex Ratio of Multiple Sclerosis in Tehran, Iran: A Population-Based Study, Iranian Journal of Public Health (2022)
102. Late-Onset Neuromyelitis Optica Spectrum Disorder: A Case Series From Iran, Revue Neurologique (2022)
103. Lifetime Physical Activity Is Associated With Gut Bacteria and Brain Health in People With Multiple Sclerosis: Focus on Physical Activity Intensity, Multiple Sclerosis and Related Disorders (2022)
104. Neonate, Infant, and Child Mortality in North Africa and Middle East by Cause: An Analysis for the Global Burden of Disease Study 2019, Archives of Iranian Medicine (2022)
105. Neonate, Infant, and Child Mortality in North Africa and Middle East by Cause: An Analysis for the Global Burden of Disease Study 2019, Archives of Iranian Medicine (2022)
106. Outcomes of Astrazeneca Vaccine for Relapse and Covid-19 Infection in People With Multiple Sclerosis; [پیامدهاي واکسن آسترازنکا در ابتلا به کووید- 19 و عود در افراد مبتلا به مالتیپل اسکلروزیس], Tehran University Medical Journal (2022)
107. Population-Level Risks of Alcohol Consumption by Amount, Geography, Age, Sex, and Year: A Systematic Analysis for the Global Burden of Disease Study 2020, The Lancet (2022)
108. Population-Level Risks of Alcohol Consumption by Amount, Geography, Age, Sex, and Year: A Systematic Analysis for the Global Burden of Disease Study 2020, The Lancet (2022)
109. Post Marketing New Adverse Effects of Oral Therapies in Multiple Sclerosis: A Systematic Review, Multiple Sclerosis and Related Disorders (2022)
110. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
111. Predictors of Catching Covid-19 Infection During Pandemic Stage in Patients With Multiple Sclerosis (Ms), International Journal of Preventive Medicine (2022)
112. Pregnancy History, Oral Contraceptive Pills Consumption (Ocps), and Risk of Multiple Sclerosis: A Systematic Review and Meta-Analysis, International Journal of Preventive Medicine (2022)
113. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
114. Prescription Trends of Disease-Modifying Treatments for Multiple Sclerosis in Iran Over the Past 30 Years, Multiple Sclerosis and Related Disorders (2022)
115. Prevalence of Multiple Sclerosis and Its Clinical and Demographic Characteristics in Kurdish Populations in Western Iran (2020), Multiple Sclerosis and Related Disorders (2022)
116. Telemedicine As a Strategic Intervention for Cognitive Rehabilitation in Ms Patients During Covid-19, Acta Neurologica Belgica (2022)
117. The Association Between Body Mass Index, Demographic and Clinical Characteristics With Cognitive Performance in Patients With Neuromyelitis Optica Spectrum Disorder, Current Journal of Neurology (2022)
118. The Impact of Brain Lesions on Sexual Dysfunction in Patients With Multiple Sclerosis: A Systematic Review of Magnetic Resonance Imaging Studies: Ms Brain Lesions and Sexual Dysfunction, Multiple Sclerosis and Related Disorders (2022)
119. The Perspective of Iranian Patients With Multiple Sclerosis on the Third Dose of Covid-19 Vaccine, Current Journal of Neurology (2022)
120. The Study of Covid-19 Infection Following Vaccination in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2022)
121. The Use of Evidence-Informed Deliberative Processes for Health Insurance Benefit Package Revision in Iran, International Journal of Health Policy and Management (2022)
122. A Focus on Allogeneic Mesenchymal Stromal Cells As a Versatile Therapeutic Tool for Treating Multiple Sclerosis, Stem Cell Research and Therapy (2021)
123. Adverse Events Reported by Iranian Patients With Multiple Sclerosis After the First Dose of Sinopharm Bbibp-Corv, Vaccine (2021)
124. Age and Sex Adjusted Prevalence and Annual Incidence of Multiple Sclerosis in East-Azerbaijan, Iran, Multiple Sclerosis and Related Disorders (2021)
125. Air Pollution Is a Risk Factor for Multiple Sclerosis – Commentary, Multiple Sclerosis Journal (2021)
126. Anemia Prevalence in Women of Reproductive Age in Low- and Middle-Income Countries Between 2000 and 2018, Nature Medicine (2021)
127. Anemia Prevalence in Women of Reproductive Age in Low- and Middle-Income Countries Between 2000 and 2018, Nature Medicine (2021)
128. Anti-Lingo -1 Improved Remyelination and Neurobehavioral Deficit in Cuprizone-Induced Demyelination, Iranian Journal of Basic Medical Sciences (2021)
129. Anti-N-Methyl-D-Aspartate Receptor Encephalitis in a Patient With Multiple Sclerosis on Dimethyl Fumarate: A Case Report, Neurological Sciences (2021)
130. Attitudes Toward Vaccination in Patients With Multiple Sclerosis: A Report From Iran, Multiple Sclerosis and Related Disorders (2021)
131. Beta-Thalassemia Intermedia With Ischemic Transients Misdiagnosed As Multiple Sclerosis: A Case Report, Current Journal of Neurology (2021)
132. Burden of Multiple Sclerosis in Iran From 1990 to 2017, BMC Neurology (2021)
133. Causes of Blindness and Vision Impairment in 2020 and Trends Over 30 Years, and Prevalence of Avoidable Blindness in Relation to Vision 2020: The Right to Sight: An Analysis for the Global Burden of Disease Study, The Lancet Global Health (2021)
134. Changes in Dna Methylation in Apoe and Ackr3 Genes in Multiple Sclerosis Patients and the Relationship With Their Heavy Metal Blood Levels, NeuroToxicology (2021)
135. Changes in Dna Methylation in Apoe and Ackr3 Genes in Multiple Sclerosis Patients and the Relationship With Their Heavy Metal Blood Levels, NeuroToxicology (2021)
136. Cladribine Tablets Are a Cost-Effective Strategy in High-Disease Activity Relapsing Multiple Sclerosis Patients in Iran, Current Journal of Neurology (2021)
137. Clinical Features of Late-Onset Multiple Sclerosis: A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
138. Correlation Between the Clinical Disability and T1 Hypointense Lesions’ Volume in Cerebral Magnetic Resonance Imaging of Multiple Sclerosis Patients: A Systematic Review and Meta-Analysis, CNS Neuroscience and Therapeutics (2021)
139. Cost-Effectiveness of Ocrelizumab for Treatment of Iranian Patients With Relapsing Multiple Sclerosis, Current Journal of Neurology (2021)
140. Covid-19 and Disease-Modifying Therapies in Patients With Demyelinating Diseases of the Central Nervous System: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)
141. Demographic Features, Behavioral Measures, and Clinical Factors As Predictors of Cognitive Function in Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2021)
142. Dietary Risk Factors of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2021)
143. Economic Sanctions Against Iran As an Important Factor in Threatening the Health of Patients With Multiple Sclerosis, Current Journal of Neurology (2021)
144. Environmental Risk Factors of Multiple Sclerosis in the Middle East and North Africa Region: A Systematic Review, Current Journal of Neurology (2021)
145. Exome Sequencing Reveals Novel Rare Variants in Iranian Familial Multiple Sclerosis: The Importance of Pold2 in the Disease Pathogenesis, Genomics (2021)
146. Global Mortality From Dementia: Application of a Newmethod and Results From the Global Burden of Disease Study 2019, Alzheimer's and Dementia: Translational Research and Clinical Interventions (2021)
147. Global, Regional, and National Mortality Among Young People Aged 10–24 Years, 1950–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2021)
148. Global, Regional, and National Mortality Among Young People Aged 10–24 Years, 1950–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2021)
149. Home-Based Exercise Training Influences Gut Bacterial Levels in Multiple Sclerosis, Complementary Therapies in Clinical Practice (2021)
150. Illuminating the in Vitro Effects of Epstein-Barr Virus and Vitamin D on Immune Response in Multiple Sclerosis Patients, Journal of NeuroVirology (2021)
151. Implementing Coronavirus Disease 2019 Scale-Up Registry Protocol in National Multiple Sclerosis Registry System of Iran, Current Journal of Neurology (2021)
152. Ischemic Stroke in Patients With Covid-19 Disease: A Report of 10 Cases From Iran, Cerebrovascular Diseases (2021)
153. Mapping Routine Measles Vaccination in Low- and Middle-Income Countries, Nature (2021)
154. Mapping Routine Measles Vaccination in Low- and Middle-Income Countries, Nature (2021)
155. Measuring Routine Childhood Vaccination Coverage in 204 Countries and Territories, 1980–2019: A Systematic Analysis for the Global Burden of Disease Study 2020, Release 1, The Lancet (2021)
156. Medical History Risk Factors in Primary Progressive Multiple Sclerosis: A Case-Control Study, Current Journal of Neurology (2021)
157. Multiple Sclerosis Projection in Tehran, Iran Using Bayesian Structural Time Series, BMC Neurology (2021)
158. Neuromyelitis Optica Spectrum Disorder (Nmosd) Associated With Cancer: A Systematic Review, Multiple Sclerosis and Related Disorders (2021)
159. Physical Activity May Contribute to Brain Health in Multiple Sclerosis: An Mr Volumetric and Spectroscopy Study, Journal of Neuroimaging (2021)
160. Physicians’ Opinions on the Necessity of Covid-19 Vaccination in Patients With Epilepsy, Epileptic Disorders (2021)
161. Pregnancy Outcome in Patients With Multiple Sclerosis Treated With Rituximab: A Case-Series Study, Multiple Sclerosis and Related Disorders (2021)
162. Pregnancy Outcome in Patients With Multiple Sclerosis Treated With Rituximab: A Case-Series Study, Multiple Sclerosis and Related Disorders (2021)
163. Pregnancy Outcome in Patients With Neuromyelitis Optica Spectrum Disorder Treated With Rituximab: A Case-Series Study, Caspian Journal of Internal Medicine (2021)
164. Pregnancy Outcome in Patients With Neuromyelitis Optica Spectrum Disorder Treated With Rituximab: A Case-Series Study, Caspian Journal of Internal Medicine (2021)
165. Prevalence and Incidence of Multiple Sclerosis in Ardabil, Northwest of Iran, Multiple Sclerosis and Related Disorders (2021)
166. Prevalence of Multiple Sclerosis and Its Risks in Tehran, Iran, in 2019, Neurological Sciences (2021)
167. Reduction in Circulating Vitamin D Binding Protein in Patients With Multiple Sclerosis, BMC Neurology (2021)
168. Rna Sequencing of Cd4+ T Cells in Relapsing–Remitting Multiple Sclerosis Patients at Relapse: Deciphering the Involvement of Novel Genes and Pathways, Journal of Molecular Neuroscience (2021)
169. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
170. Safety and Efficacy of Fingolimod in Iranian Patients With Relapsing-Remitting Multiple Sclerosis: An Open-Label Study, Caspian Journal of Internal Medicine (2021)
171. Sleep Disorders As a Possible Predisposing Attack Factor in Neuromyelitis Optica Spectrum Disorder (Nmosd): A Case-Control Study, Clinical Neurology and Neurosurgery (2021)
172. Stressful Life Events and the Risk of Primary Progressive Multiple Sclerosis: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2021)
173. The Association Between Dietary Total Antioxidant Capacity and Nmo-Igg Seropositivity in Patients With Neuromyelitis Optica Spectrum Disorder, Clinical Neurology and Neurosurgery (2021)
174. The Association of Ebv and Hhv-6 Viral Load With Different Nk and Cd8+ T Cell Subsets in the Acute Phase of Relapsing-Remitting Multiple Sclerosis, Cell Journal (2021)
175. The Contribution of Self-Disclosure to the Prediction of Mood Symptoms in Patients With Multiple Sclerosis, Current Journal of Neurology (2021)
176. The Contribution of Self-Disclosure to the Prediction of Mood Symptoms in Patients With Multiple Sclerosis, Current Journal of Neurology (2021)
177. The Factors Associated With Olfactory Dysfunction in Patients With Multiple Sclerosis, Basic and Clinical Neuroscience (2021)
178. The First Presentation of Covid-19 Two Hours After Vaccination in a Patient With Multiple Sclerosis: Can Covid Vaccine Provoke Cytokine Storm in a Patient With Asymptomatic Covid-19?, Current Journal of Neurology (2021)
179. The Possible Direct Correlation Between Cognitive Impairment and Fear of Catching Covid-19 Among Patients With Multiple Sclerosis, Iranian Journal of Psychiatry (2021)
180. The Possible Role of Interleukin-6 As a Regulator of Insulin Sensitivity in Patients With Neuromyelitis Optica Spectrum Disorder, BMC Neurology (2021)
181. The Prevalence of Cognitive Impairment in Patients With Neuromyelitis Optica Spectrum Disorders (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
182. The Prevalence of Cognitive Impairment in Patients With Neuromyelitis Optica Spectrum Disorders (Nmosd): A Systematic Review and Meta-Analysis, Multiple Sclerosis and Related Disorders (2021)
183. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
184. The Prevalence of Covid-19 Infection in Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Neurological Sciences (2021)
185. Tracking Development Assistance for Health and for Covid-19: A Review of Development Assistance, Government, Out-Of-Pocket, and Other Private Spending on Health for 204 Countries and Territories, 1990–2050, The Lancet (2021)
186. Tracking Development Assistance for Health and for Covid-19: A Review of Development Assistance, Government, Out-Of-Pocket, and Other Private Spending on Health for 204 Countries and Territories, 1990–2050, The Lancet (2021)
187. Translation and Validation of the Persian Version of Godin Leisure-Time Exercise Questionnaire in Patients With Multiple Sclerosis, BMC Neurology (2021)
188. Treatment With 25-Hydroxyvitamin D3 (Calcifediol) Is Associated With a Reduction in the Blood Neutrophil-To-Lymphocyte Ratio Marker of Disease Severity in Hospitalized Patients With Covid-19: A Pilot Multicenter, Randomized, Placebo-Controlled, Double-Blinded Clinical Trial, Endocrine Practice (2021)
189. Umbilical Cord Mesenchymal Stem Cells As Well As Their Released Exosomes Suppress Proliferation of Activated Pbmcs in Multiple Sclerosis, Scandinavian Journal of Immunology (2021)
190. Use of Multidimensional Item Response Theory Methods for Dementia Prevalence Prediction: An Example Using the Health and Retirement Survey and the Aging, Demographics, and Memory Study, BMC Medical Informatics and Decision Making (2021)
191. Vitamin D Changes Expression of Dna Repair Genes in the Patients With Multiple Sclerosis, Gene (2021)
192. Whole Grains and Legumes Consumption in Association With Neuromyelitis Optica Spectrum Disorder Odds, Current Journal of Neurology (2021)
193. Widespread Disruptions of White Matter in Familial Multiple Sclerosis: Dti and Noddi Study, Frontiers in Neurology (2021)
194. A Case of Possible Atypical Demyelinating Event of the Central Nervous System Following Covid-19, Multiple Sclerosis and Related Disorders (2020)
195. A Randomized Controlled Trial Investigating the Effects of a Mediterranean-Like Diet in Patients With Multiple Sclerosis-Associated Cognitive Impairments and Fatigue, Current Journal of Neurology (2020)
196. Aggressive Course of Cognitive Impairment in Multiple Sclerosis: A New Term for the Management of Patients, Journal of Clinical Neuroscience (2020)
197. Analysis of Single Nucleotide Polymorphisms in Hla-Dra, Il2ra, and Hmgb1 Genes in Multiple Sclerosis, Reports of Biochemistry and Molecular Biology (2020)
198. Association of Hla-Dra and Il2ra Polymorphisms With the Severity and Relapses Rate of Multiple Sclerosis in an Iranian Population, Reports of Biochemistry and Molecular Biology (2020)
199. Author Correction: Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017 (Nature Medicine, (2020), 26, 5, (750-759), 10.1038/S41591-020-0807-6), Nature Medicine (2020)
200. Author Correction: Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017 (Nature Medicine, (2020), 26, 5, (750-759), 10.1038/S41591-020-0807-6), Nature Medicine (2020)
201. Burden of Musculoskeletal Disorders in Iran During 1990–2017: Estimates From the Global Burden of Disease Study 2017, Archives of Osteoporosis (2020)
202. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: 2019 Revisions to the Menactrims Guidelines, Multiple Sclerosis and Related Disorders (2020)
203. Department of Error: Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000–17: Analysis for the Global Burden of Disease Study 2017 (The Lancet (2020) 395(10239) (1779–1801), (S0140673620301148), (10.1016/S0140-6736(20)30114-8)), The Lancet (2020)
204. Department of Error: Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000–17: Analysis for the Global Burden of Disease Study 2017 (The Lancet (2020) 395(10239) (1779–1801), (S0140673620301148), (10.1016/S0140-6736(20)30114-8)), The Lancet (2020)
205. Dietary Total Antioxidant Capacity and Neuromyelitis Optica Spectrum Disorder Susceptibility, Nutrition and Food Science (2020)
206. Efficacy and Safety of Rituximab in Patients With Refractory Neuromyelitis Optica Spectrum Disorders: A Prospective Observation in Iranian Cases, Caspian Journal of Internal Medicine (2020)
207. Efficacy and Safety of Rituximab in Treating Patients With Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Autoimmunity Reviews (2020)
208. Epidemiology of Familial Multiple Sclerosis: A Population-Based Study in Tehran During 1999–2018, Multiple Sclerosis and Related Disorders (2020)
209. Epidemiology of Neuromyelitis Optica Spectrum Disorder in Tehran, Iran: The Prevalence, Baseline Characteristics, and Clinical Aspects, Neurological Sciences (2020)
210. Evaluation of Covid-19 Infection in Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd): A Report From Iran, Multiple Sclerosis and Related Disorders (2020)
211. Evaluation of Emotional Intelligence (Ei) in Neuromyelitis Optica Spectrum Disorder (Nmosd) Patients Compared to Healthy Individuals, Multiple Sclerosis and Related Disorders (2020)
212. Evaluation of the Opinion of Patients With Multiple Sclerosis on the Outcomes of Catching Covid-19 and Its Effects on the Ms Symptoms, Basic and Clinical Neuroscience (2020)
213. Evaluation of the Rate of Covid-19 Infection, Hospitalization and Death Among Iranian Patients With Multiple Sclerosis, Multiple Sclerosis and Related Disorders (2020)
214. Evaluation of Types of Psychological Disorders in Patients With Neuromyelitis Optica Spectrum Disorder (Nmosd), Multiple Sclerosis and Related Disorders (2020)
215. Evidence of an Increased Prevalence of Multiple Sclerosis: A Population-Based Study of Tehran Registry During 1999-2018, BMC Neurology (2020)
216. Five Insights From the Global Burden of Disease Study 2019, The Lancet (2020)
217. Five Insights From the Global Burden of Disease Study 2019, The Lancet (2020)
218. Global Age-Sex-Specific Fertility, Mortality, Healthy Life Expectancy (Hale), and Population Estimates in 204 Countries and Territories, 1950–2019: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
219. Global Age-Sex-Specific Fertility, Mortality, Healthy Life Expectancy (Hale), and Population Estimates in 204 Countries and Territories, 1950–2019: A Comprehensive Demographic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
220. Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
221. Global Burden of 369 Diseases and Injuries in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
222. Health Sector Spending and Spending on Hiv/Aids, Tuberculosis, and Malaria, and Development Assistance for Health: Progress Towards Sustainable Development Goal 3, The Lancet (2020)
223. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
224. Immune Reconstitution Therapy or Continuous Immunosuppression for the Management of Active Relapsing–Remitting Multiple Sclerosis Patients? a Narrative Review, Neurology and Therapy (2020)
225. Impact of Supplementation With Multivitamin-Mineral Specially Formulated to Improve Fatigue and Inflammatory State in Patients With Multiple Sclerosis: A Triple-Blind, Randomized, Placebo-Controlled Trial, Current Journal of Neurology (2020)
226. Incidence of Seroconversion and Sero-Reversion in Patients With Multiple Sclerosis (Ms) Who Had Been Treated With Natalizumab: A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2020)
227. Knowledge Regarding Covid-19 Pandemic in Patients With Multiple Sclerosis (Ms): A Report From Iran, Multiple Sclerosis and Related Disorders (2020)
228. Mapping Geographical Inequalities in Access to Drinking Water and Sanitation Facilities in Low-Income and Middle-Income Countries, 2000-17, The Lancet Global Health (2020)
229. Mapping Geographical Inequalities in Access to Drinking Water and Sanitation Facilities in Low-Income and Middle-Income Countries, 2000-17, The Lancet Global Health (2020)
230. Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000-17: Analysis for the Global Burden of Disease Study 2017, The Lancet (2020)
231. Mapping Geographical Inequalities in Childhood Diarrhoeal Morbidity and Mortality in Low-Income and Middle-Income Countries, 2000-17: Analysis for the Global Burden of Disease Study 2017, The Lancet (2020)
232. Mapping Geographical Inequalities in Oral Rehydration Therapy Coverage in Low-Income and Middle-Income Countries, 2000-17, The Lancet Global Health (2020)
233. Mapping Geographical Inequalities in Oral Rehydration Therapy Coverage in Low-Income and Middle-Income Countries, 2000-17, The Lancet Global Health (2020)
234. Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017, Nature Medicine (2020)
235. Mapping Local Patterns of Childhood Overweight and Wasting in Low- and Middle-Income Countries Between 2000 and 2017, Nature Medicine (2020)
236. Measuring Universal Health Coverage Based on an Index of Effective Coverage of Health Services in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
237. Measuring Universal Health Coverage Based on an Index of Effective Coverage of Health Services in 204 Countries and Territories, 1990–2019: A Systematic Analysis for the Global Burden of Disease Study 2019, The Lancet (2020)
238. Molecular Detection of Epstein–Barr Virus, Human Herpes Virus 6, Cytomegalovirus, and Hepatitis B Virus in Patients With Multiple Sclerosis, Middle East Journal of Digestive Diseases (2020)
239. Multiple Sclerosis and Human Leukocyte Antigen Genotypes: Focus on the Middle East and North Africa Region, Multiple Sclerosis Journal - Experimental# Translational and Clinical (2020)
240. Neuro-Behcet's Disease: An Update on Diagnosis, Differential Diagnoses, and Treatment, Multiple Sclerosis and Related Disorders (2020)
241. Neuropsychiatric and Cognitive Effects of the Covid-19 Outbreak on Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2020)
242. Persian Adaptation of Actionable Bladder Symptom Screening Tool Among Patients With Multiple Sclerosis, Journal of Multidisciplinary Healthcare (2020)
243. Predictors of Suicidal Ideation Among Iranian Patients With Multiple Sclerosis, Current Journal of Neurology (2020)
244. Prevalence of Anti-Jc Virus Antibody Seropositivity in Patients With Multiple Sclerosis: A Systematic Review and Meta-Analysis, Intervirology (2020)
245. Psychiatric Advice During Covid-19 Pandemic for Patients With Multiple Sclerosis, Iranian Journal of Psychiatry and Behavioral Sciences (2020)
246. Rehabilitation Recommendations for Multiple Sclerosis Patients During the Covid-19 Pandemic, Archives of Iranian Medicine (2020)
247. Risk of Cancer in Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Autoimmunity Reviews (2020)
248. Salivary Profile and Dental Status of Patients With Multiple Sclerosis; [Profil Slinowy I Stan Uzebienia Pacjentow Ze Stwardnieniem Rozsianym], Dental and Medical Problems (2020)
249. Staphylococcal Enterotoxin B Increased Severity of Experimental Model of Multiple Sclerosis, Microbial Pathogenesis (2020)
250. Stressful Life Events, Socioeconomic Status, and the Risk of Neuromyelitis Optica Spectrum Disorder: A Population-Based Case-Control Study, Multiple Sclerosis and Related Disorders (2020)
251. The Co-Occurrence of Multiple Sclerosis and Evans Syndrome: A Case Report, Caspian Journal of Internal Medicine (2020)
252. The Health Burden of Non-Communicable Neurological Disorders in the Usa Between 1990 and 2017, Brain Communications (2020)
253. The Possible Beneficial Effects of Higher Vitamin B6 Intake From Diet on Cognitive Function of Patients With Neuromyelitis Optica Spectrum Disorder, Multiple Sclerosis and Related Disorders (2020)
254. The Prevalence of Migraine in Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2020)
255. The Prevalence of Migraine in Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, Journal of Clinical Neuroscience (2020)
256. The Putative Association of Tob1-As1 Long Non-Coding Rna With Immune Tolerance: A Study on Multiple Sclerosis Patients, NeuroMolecular Medicine (2020)
257. Thrombotic Microangiopathy in Interferon-Beta-Treated Multiple Sclerosis Patient, Clinical Case Reports (2020)
258. Tumefactive Demyelinating Lesions After Initiating Fingolimod in Patient With Multiple Sclerosis: A Case Report, Revue Neurologique (2020)
259. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
260. Tumefactive Rebound of Multiple Sclerosis After the Short-Term Cessation of Fingolimod: A Case Report, Multiple Sclerosis and Related Disorders (2020)
261. Vitamin D Sufficiency, a Serum 25-Hydroxyvitamin D at Least 30 Ng/Ml Reduced Risk for Adverse Clinical Outcomes in Patients With Covid-19 Infection, PLoS ONE (2020)
262. Age at Menarche and Risk of Multiple Sclerosis (Ms): A Systematic Review and Meta-Analysis, BMC Neurology (2019)
263. Autoimmune Diseases Associated With Neuromyelitis Optica Spectrum Disorders: A Literature Review, Multiple Sclerosis and Related Disorders (2019)
264. Burden of Neurodegenerative Diseases in the Eastern Mediterranean Region, 1990–2016: Findings From the Global Burden of Disease Study 2016, European Journal of Neurology (2019)
265. Circulating Mesenchymal Stem Cells, Stromal Derived Factor (Sdf)-1 and Ip-10 Levels Increased in Clinically Active Multiple Sclerosis Patients But Not in Clinically Stable Patients Treated With Beta Interferon, Multiple Sclerosis and Related Disorders (2019)
266. Convergent Effects of a Functional C3 Variant on Brain Atrophy, Demyelination, and Cognitive Impairment in Multiple Sclerosis, Multiple Sclerosis Journal (2019)
267. Convergent Effects of a Functional C3 Variant on Brain Atrophy, Demyelination, and Cognitive Impairment in Multiple Sclerosis, Multiple Sclerosis Journal (2019)
268. Cost-Effectiveness of Alemtuzumab and Natalizumab for Relapsing-Remitting Multiple Sclerosis Treatment in Iran: Decision Analysis Based on an Indirect Comparison, Journal of Medical Economics (2019)
269. Disability and Therapeutic Response in Paediatric Neuromyelitis Optica Spectrum Disorder a Case Series From Iran, Iranian Journal of Child Neurology (2019)
270. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
271. Erratum: Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1923–1994), (S0140673618322256), (10.1016/S0140-6736(18)32225-6)), The Lancet (2019)
272. Global, Regional, and National Burden of Neurological Disorders, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016, The Lancet Neurology (2019)
273. Global, Regional, and National Burden of Neurological Disorders, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016, The Lancet Neurology (2019)
274. Global, Regional, and National Burden of Traumatic Brain Injury and Spinal Cord Injury, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016, The Lancet Neurology (2019)
275. Global, Regional, and National Incidence, Prevalence, and Mortality of Hiv, 1980-2017, and Forecasts to 2030, for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Diseases, Injuries, and Risk Factors Study 2017, The Lancet HIV (2019)
276. Integrational Analysis of Mirnas Data Sets As a Plausible Missing Linker Between Epstein-Barr Virus and Vitamin D in Relapsing Remitting Ms Patients, Gene (2019)
277. Management of Seizures in Patients With Multiple Sclerosis; an Iranian Consensus, Epilepsy and Behavior (2019)
278. Management of Seizures in Patients With Multiple Sclerosis; an Iranian Consensus, Epilepsy and Behavior (2019)
279. Multiple Sclerosis in Tehran: Rising Prevalence Alongside Stabilizing Incidence - True Increase or Enhanced Diagnosis?, Archives of Iranian medicine (2019)
280. Multiple Sclerosis National Registry System in Iran: Validity and Reliability of a Minimum Data Set, Multiple Sclerosis and Related Disorders (2019)
281. Multiple Sclerosis National Registry System in Iran: Validity and Reliability of a Minimum Data Set, Multiple Sclerosis and Related Disorders (2019)
282. Multiple Sclerosis Pathogenesis: Missing Pieces of an Old Puzzle, Reviews in the Neurosciences (2019)
283. Pediatric Multiple Sclerosis and Its Familial Recurrence: A Population Based Study (1999–2017), Multiple Sclerosis and Related Disorders (2019)
284. Progressive Solitary Sclerosis Presented With Diplopia: A Case Report, Multiple Sclerosis and Related Disorders (2019)
285. Sccmec Genotypes of Methicillin-Resistant Staphylococcus Aureus in Nasal Carriage of Multiple Sclerosis Patients in Iran, Iranian Journal of Public Health (2019)
286. The Association Between Dietary Sugar Intake and Neuromyelitis Optica Spectrum Disorder: A Case–Control Study, Multiple Sclerosis and Related Disorders (2019)
287. The Burden of Headache Disorders in the Eastern Mediterranean Region, 1990-2016: Findings From the Global Burden of Disease Study 2016, Journal of Headache and Pain (2019)
288. The Correlation Between Dyslipidemia and Cognitive Impairment in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2019)
289. The Effect of Vitamin D Supplements on Clinical and Para-Clinical Outcomes in Patients With Multiple Sclerosis: Protocol for a Systematic Review, JMIR Research Protocols (2019)
290. The Prevalence of the Genetic Polymorphism of Gstm1, Gstt1 and Gstp1 and Its Relationship With Clinical Criteria of Multiple Sclerosis (Ms) Patients in Tehran, Journal of Babol University of Medical Sciences (2019)
291. The Prevalence of the Genetic Polymorphism of Gstm1, Gstt1 and Gstp1 and Its Relationship With Clinical Criteria of Multiple Sclerosis (Ms) Patients in Tehran, Journal of Babol University of Medical Sciences (2019)
292. The Relationship Between Cognitive Function and Body Mass Index in Multiple Sclerosis Patients, Multiple Sclerosis and Related Disorders (2019)
293. Therapeutic Use of Intrathecal Mesenchymal Stem Cells in Patients With Multiple Sclerosis: A Pilot Study With Booster Injection, Immunological Investigations (2019)
294. A Case of Dextrocardia Following Maternal Exposure to Generic Fingolimod During the First Trimester of Pregnancy, Multiple Sclerosis and Related Disorders (2018)
295. A Comparison of Pediatric and Adult Neuromyelitis Optica Spectrum Disorders: A Review of Clinical Manifestation, Diagnosis, and Treatment, Journal of the Neurological Sciences (2018)
296. A Presentation of Ulcerative Colitis After Rituximab Therapy in a Patient With Multiple Sclerosis and Literature Review, Multiple Sclerosis and Related Disorders (2018)
297. A Systems Medicine Approach Reveals Disordered Immune System and Lipid Metabolism in Multiple Sclerosis Patients, Clinical and Experimental Immunology (2018)
298. Anti-Jc Virus Antibody Sera Positivity and Index Value Among Patients With Multiple Sclerosis May Be Correlated With Age, Sex, and Area of Residence, Journal of NeuroVirology (2018)
299. B Cells in Multiple Sclerosis Therapy—A Comprehensive Review, Acta Neurologica Scandinavica (2018)
300. Balo's Concentric Sclerosis: An Update and Comprehensive Literature Review, Reviews in the Neurosciences (2018)
301. Burden of Diarrhea in the Eastern Mediterranean Region, 1990–2015: Findings From the Global Burden of Disease 2015 Study, International Journal of Public Health (2018)
302. Burden of Obesity in the Eastern Mediterranean Region: Findings From the Global Burden of Disease 2015 Study, International Journal of Public Health (2018)
303. Characterization of Cd4+ and Cd8+ T Cell Subsets and Interferon Regulatory Factor 4 (Irf4) in Ms Patients Treated With Fingolimod (Fty-720); a Follow-Up Study, Iranian Journal of Allergy# Asthma and Immunology (2018)
304. Dashboard of Multiple Sclerosis Surveillance Registry: Developing Its Key Performance Indicators, Acta Medica Mediterranea (2018)
305. Demyelination With Preferential Mag Loss: A Complex Message From Ms Paraffin Blocks, Journal of the Neurological Sciences (2018)
306. Early-Onset Multiple Sclerosis: Reports of 300 Patients From Iran, Journal of Pediatric Neurosciences (2018)
307. Effects of 8-Week Home-Based Yoga and Resistance Training on Muscle Strength, Functional Capacity and Balance in Patients With Multiple Sclerosis: A Randomized Controlled Study, Asian Journal of Sports Medicine (2018)
308. Efficacy and Safety of Natalizumab Extended Interval Dosing, Multiple Sclerosis and Related Disorders (2018)
309. Environmental Risk Factors in Neuromyelitis Optica Spectrum Disorder: A Case–Control Study, Acta Neurologica Belgica (2018)
310. Erratum: Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7)), The Lancet (2018)
311. Erratum: Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017 (The Lancet (2018) 392(10159) (1736–1788)(S0140673618322037)(10.1016/S0140-6736(18)32203-7)), The Lancet (2018)
312. Estimating the Marginal Causal Effect of Fish Consumption During Adolescence on Multiple Sclerosis: A Population-Based Incident Case-Control Study, Neuroepidemiology (2018)
313. Global, Regional, and National Age-Sex-Specific Mortality and Life Expectancy, 1950-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
314. Global, Regional, and National Age-Sex-Specific Mortality and Life Expectancy, 1950-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
315. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
316. Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
317. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
318. Global, Regional, and National Comparative Risk Assessment of 84 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
319. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
320. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 359 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
321. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
322. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 354 Diseases and Injuries for 195 Countries and Territories, 1990-2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
323. Hla-Drb1 Polymorphism and Susceptibility to Multiple Sclerosis in the Middle East North Africa Region: A Systematic Review and Meta-Analysis, Journal of Neuroimmunology (2018)
324. Hotair But Not Anril Long Non-Coding Rna Contributes to the Pathogenesis of Multiple Sclerosis, Immunology (2018)
325. Human Herpesvirus 8 Dna Detection and Variant Analysis in Patients With Multiple Sclerosis, VirusDisease (2018)
326. Increasing Prevalence of Familial Recurrence of Multiple Sclerosis in Iran: A Population Based Study of Tehran Registry 1999-2015, BMC Neurology (2018)
327. Influence of Nationality on the Brief International Cognitive Assessment for Multiple Sclerosis (Bicams), Clinical Neuropsychologist (2018)
328. Lifestyle Factors and Multiple Sclerosis: A Population-Based Incident Case-Control Study, Multiple Sclerosis and Related Disorders (2018)
329. Maternal Mortality and Morbidity Burden in the Eastern Mediterranean Region: Findings From the Global Burden of Disease 2015 Study, International Journal of Public Health (2018)
330. Measuring Performance on the Healthcare Access and Quality Index for 195 Countries and Territories and Selected Subnational Locations: A Systematic Analysis From the Global Burden of Disease Study 2016, The Lancet (2018)
331. Measuring Performance on the Healthcare Access and Quality Index for 195 Countries and Territories and Selected Subnational Locations: A Systematic Analysis From the Global Burden of Disease Study 2016, The Lancet (2018)
332. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
333. Measuring Progress From 1990 to 2017 and Projecting Attainment to 2030 of the Health-Related Sustainable Development Goals for 195 Countries and Territories: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
334. Multiple Sclerosis: Clinical Features, Pathophysiology, Diagnosis, and Management, Neuroinflammation (2018)
335. No Association Between Socioeconomic Status and Risk of Multiple Sclerosis: A Population-Based Incident Case-Control Study in a Developing Country, Multiple Sclerosis and Related Disorders (2018)
336. Parental Ethnicity Associated With Risk for Multiple Sclerosis: A Population-Based Incident Case–Control Study in Iran, Multiple Sclerosis and Related Disorders (2018)
337. Perceived Social Stigma in Patients With Multiple Sclerosis: A Study From Iran, Acta Neurologica Taiwanica (2018)
338. Perspectives of Medieval Persian Medicine on Multiple Sclerosis, Current Drug Metabolism (2018)
339. Population and Fertility by Age and Sex for 195 Countries and Territories, 1950–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
340. Population and Fertility by Age and Sex for 195 Countries and Territories, 1950–2017: A Systematic Analysis for the Global Burden of Disease Study 2017, The Lancet (2018)
341. Primary Progressive Multiple Sclerosis in Iran: A Consensus Recommendation for Diagnosis and Management, Multiple Sclerosis and Related Disorders (2018)
342. Primary Progressive Multiple Sclerosis in Iran: A Consensus Recommendation for Diagnosis and Management, Multiple Sclerosis and Related Disorders (2018)
343. Smoking and Worsening Disability in Multiple Sclerosis: A Meta-Analysis, Acta Neurologica Scandinavica (2018)
344. The Prevalence, Incidence and Familial Recurrence of Multiple Sclerosis in Tehran, Iran, Multiple Sclerosis and Related Disorders (2018)
345. Trends in Hiv/Aids Morbidity and Mortality in Eastern Mediterranean Countries, 1990–2015: Findings From the Global Burden of Disease 2015 Study, International Journal of Public Health (2018)
346. Uncovering the Link Between Reproductive Factors and Multiple Sclerosis: A Case-Control Study on Iranian Females, Multiple Sclerosis and Related Disorders (2018)
347. Alteration of Ogg1, Myh and Mth1 Genes Expression in Relapsing-Remitting Multiple Sclerosis Patients, Physiology and Pharmacology (2017)
348. Burden of Skin and Subcutaneous Diseases in Iran and Neighboring Countries: Results From the Global Burden of Disease Study 2015, Archives of Iranian Medicine (2017)
349. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
350. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)
351. Comparing Epidemiology and Baseline Characteristic of Multiple Sclerosis and Neuromyelitis Optica: A Case-Control Study, Multiple Sclerosis and Related Disorders (2017)
352. Correlation Between Heavy Metal Exposure and Gstm1 Polymorphism in Iranian Multiple Sclerosis Patients, Neurological Sciences (2017)
353. Correlation Between Heavy Metal Exposure and Gstm1 Polymorphism in Iranian Multiple Sclerosis Patients, Neurological Sciences (2017)
354. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
355. Diagnosis and Management of Neuromyelitis Optica Spectrum Disorder (Nmosd) in Iran: A Consensus Guideline and Recommendations, Multiple Sclerosis and Related Disorders (2017)
356. Disability-Adjusted Life-Years (Dalys) for 315 Diseases and Injuries and Healthy Life Expectancy (Hale) in Iran and Its Neighboring Countries, 1990–2015: Findings From Global Burden of Disease Study 2015, Archives of Iranian Medicine (2017)
357. Exercise Prescription for Patients With Multiple Sclerosis; Potential Benefits and Practical Recommendations, BMC Neurology (2017)
358. Global, Regional, and National Burden of Neurological Disorders During 1990–2015: A Systematic Analysis for the Global Burden of Disease Study 2015, The Lancet Neurology (2017)
359. Global, Regional, and National Disability-Adjusted Life-Years (Dalys) for 333 Diseases and Injuries and Healthy Life Expectancy (Hale) for 195 Countries and Territories, 1990-2016: A Systematic Analysis for the Global Burden of Disease Study 2016, The Lancet (2017)
360. Global, Regional, and National Under-5 Mortality, Adult Mortality, Age-Specific Mortality, and Life Expectancy, 1970-2016: A Systematic Analysis for the Global Burden of Disease Study 2016, The Lancet (2017)
361. Healthcare Access and Quality Index Based on Mortality From Causes Amenable to Personal Health Care in 195 Countries and Territories, 1990-2015: A Novel Analysis From the Global Burden of Disease Study 2015, The Lancet (2017)
362. Human Herpes Virus 6 Status in Relapsing-Remitting Multiple Sclerosis Patients, Internal Medicine Journal (2017)
363. Intervening to Reduce the Risk of Future Disability From Multiple Sclerosis: Are We There Yet?, International Journal of Neuroscience (2017)
364. Intra-Rater Reliability of the Modified Tardieu Scale in Patients With Multiple Sclerosis, Neurological Sciences (2017)
365. Multiple Sclerosis and Air Pollution Exposure: Mechanisms Toward Brain Autoimmunity, Medical Hypotheses (2017)
366. Multiple Sclerosis-Associated Retrovirus, Epstein-Barr Virus, and Vitamin D Status in Patients With Relapsing Remitting Multiple Sclerosis, Journal of Medical Virology (2017)
367. Neuromyelitis Optica Spectrum Disorders in Iran, Multiple Sclerosis and Related Disorders (2017)
368. Polymorphisms of Rps6kb1 and Cd86 Associates With Susceptibility to Multiple Sclerosis in Iranian Population, Neurological Research (2017)
369. Prevalence and Incidence of Multiple Sclerosis in Tehran, Iran, Iranian Journal of Public Health (2017)
370. Prevalence of Sea, Seb, Sec, Sed, and Tsst-1 Genes of Staphylococcus Aureus in Nasal Carriage and Their Association With Multiple Sclerosis, GERMS (2017)
371. Psychometric Evaluation of the Persian Version of the Chronic Illness Anticipated Stigma Scale (Ciass), International Journal of Behavioral Medicine (2017)
372. Reply to Urbanization Theory for Growing Trend of Multiple Sclerosis Letter, Iranian Journal of Public Health (2017)
373. Sleep Disorder As a Triggering Factor for Relapse in Multiple Sclerosis, European Neurology (2017)
374. The Expression of Lnc-Il-7R Long Non-Coding Rna Dramatically Correlated With Soluble and Membrane-Bound Isoforms of Il-7Ra Gene in Multiple Sclerosis Patients, Neuroscience Letters (2017)
375. Utility of Myelin Basic Protein As an Early Prognostic Biomarker in Multiple Sclerosis, Iranian Red Crescent Medical Journal (2017)
376. Waterpipe Smoking Associated With Multiple Sclerosis: A Population-Based Incident Case–Control Study, Multiple Sclerosis (2017)
377. Association of Two Polymorphisms in Msh2 and Xrcc1 Genes With Multiple Sclerosis in Iranian Population, Physiology and Pharmacology (2016)
378. Association Study of Two Functional Single Nucleotide Polymorphisms of Neuropeptide Y Gene With Multiple Sclerosis, Neuropeptides (2016)
379. Behavioral Neurology of Multiple Sclerosis and Autoimmune Encephalopathies, Neurologic Clinics (2016)
380. Blood Concentrations of Cadmium and Lead in Multiple Sclerosis Patients From Iran, Iranian Journal of Pharmaceutical Research (2016)
381. Channelopathy-Related Scn10a Gene Variants Predict Cerebellar Dysfunction in Multiple Sclerosis, Neurology (2016)
382. Concomitant Multiple Sclerosis and Another Autoimmune Disease: Does the Clinical Course Change?, Clinical Neurology and Neurosurgery (2016)
383. Differential Frequency of Cd8+ T Cell Subsets in Multiple Sclerosis Patients With Various Clinical Patterns, PLoS ONE (2016)
384. Ebv and Vitamin D Status in Relapsing-Remitting Multiple Sclerosis Patients With a Unique Cytokine Signature, Medical Microbiology and Immunology (2016)
385. Effect of Vitamin a Supplementation on Fatigue and Depression in Multiple Sclerosis Patients: A Double-Blind Placebo-Controlled Clinical Trial, Iranian Journal of Allergy# Asthma and Immunology (2016)
386. Evidence for Possible Role of Melatonin in Reducing Oxidative Stress in Multiple Sclerosis Through Its Effect on Sirt1 and Antioxidant Enzymes, Life Sciences (2016)
387. Gray Matter Mri Differentiates Neuromyelitis Optica From Multiple Sclerosis Using Random Forest, Neurology (2016)
388. Health in Times of Uncertainty in the Eastern Mediterranean Region, 1990–2013: A Systematic Analysis for the Global Burden of Disease Study 2013, The Lancet Global Health (2016)
389. Iranian Consensus on Use of Vitamin D in Patients With Multiple Sclerosis, BMC Neurology (2016)
390. Iranian Consensus on Use of Vitamin D in Patients With Multiple Sclerosis, BMC Neurology (2016)
391. Jc Virus Seroprevalence and Seroconversion in Multiple Sclerosis Cohort: A Middle-Eastern Study, Journal of the Neurological Sciences (2016)
392. Leukocyte Gene Expression and Plasma Concentration in Multiple Sclerosis: Alteration of Transforming Growth Factor-Βs, Claudin-11, and Matrix Metalloproteinase-2, Cellular and Molecular Neurobiology (2016)
393. Multiple Sclerosis Epidemiology in East Asia, South East Asia and South Asia: A Systematic Review, Neuroepidemiology (2016)
394. Neuromyelitis Optica and Pregnancy, Acta Neurologica Belgica (2016)
395. Persian Adaptation of a Questionnaire of Environmental Risk Factors in Multiple Sclerosis (Envims-Q), Multiple Sclerosis and Related Disorders (2016)
396. Prevalence of Multiple Sclerosis in Iranian Emigrants: Review of the Evidence, Neurological Sciences (2016)
397. Prevalence of Multiple Sclerosis in Iranian Emigrants: Review of the Evidence, Neurological Sciences (2016)
398. Quantitative Evaluation of Baff, Hmgb1, Tlr 4 and Tlr 7 Expression in Patients With Relapsing Remitting Multiple Sclerosis, Iranian Journal of Allergy# Asthma and Immunology (2016)
399. Retinyl Palmitate Supplementation Modulates T-Bet and Interferon Gamma Gene Expression in Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2016)
400. Validity and Reliability of the Persian Version of the Perception De La Scle’Rose En Plaques Et De Ses Pousse’Es Questionnaire Evaluating Multiple Sclerosis-Related Quality of Life, International Journal of Preventive Medicine (2016)
401. Classification Algorithms With Multi-Modal Data Fusion Could Accurately Distinguish Neuromyelitis Optica From Multiple Sclerosis, NeuroImage: Clinical (2015)
402. Consensus Recommendations for the Diagnosis and Treatment of Multiple Sclerosis: The Middle East North Africa Committee for Treatment and Research in Multiple Sclerosis (Menactrims), Current Medical Research and Opinion (2015)
403. Dominant and Protective Role of the Cyth4 Primate-Specific Gttt-Repeat Longer Alleles Against Neurodegeneration, Journal of Molecular Neuroscience (2015)
404. Effect of Vitamin D Treatment on Interleukin-2 and Interleukin-4 Genes Expression in Multiple Sclerosis, Physiology and Pharmacology (2015)
405. Effects of Eight-Week Resistance Training Program in Men With Multiple Sclerosis, Asian Journal of Sports Medicine (2015)
406. Functional Clinical Outcomes in Multiple Sclerosis: Current Status and Future Prospects, Multiple Sclerosis and Related Disorders (2015)
407. Global, Regional, and National Age-Sex Specific All-Cause and Cause-Specific Mortality for 240 Causes of Death, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013, The Lancet (2015)
408. Global, Regional, and National Comparative Risk Assessment of 79 Behavioural, Environmental and Occupational, and Metabolic Risks or Clusters of Risks in 188 Countries, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013, The Lancet (2015)
409. Global, Regional, and National Disability-Adjusted Life Years (Dalys) for 306 Diseases and Injuries and Healthy Life Expectancy (Hale) for 188 Countries, 1990-2013: Quantifying the Epidemiological Transition, The Lancet (2015)
410. Global, Regional, and National Incidence, Prevalence, and Years Lived With Disability for 301 Acute and Chronic Diseases and Injuries in 188 Countries, 1990-2013: A Systematic Analysis for the Global Burden of Disease Study 2013, The Lancet (2015)
411. Impact of Melatonin on Motor, Cognitive and Neuroimaging Indices in Patients With Multiple Sclerosis, Iranian Journal of Allergy# Asthma and Immunology (2015)
412. Impact of Vitamin a Supplementation on Disease Progression in Patients With Multiple Sclerosis, Archives of Iranian Medicine (2015)
413. Interleukin-10 But Not Transforming Growth Factor-Β1 Gene Expression Is Up-Regulated by Vitamin D Treatment in Multiple, Journal of the Neurological Sciences (2015)
414. Multiple Sclerosis Epidemiology in Middle East and North Africa: A Systematic Review and Meta-Analysis, Neuroepidemiology (2015)
415. Neuromyelitis Optica With Linear Enhancement of Corpus Callosum in Brain Magnetic Resonance Imaging With Contrast: A Case Report, Journal of Medical Case Reports (2015)
416. Potential Role of Immunoglobulin Replacement Therapy on Mri Measures in Multiple Sclerosis: A Systematic Review, Expert Review of Clinical Immunology (2015)
417. The Effect of Vitamin a Supplementation on Foxp3 and Tgf-Β Gene Expression in Avonex-Treated Multiple Sclerosis Patients, Journal of Molecular Neuroscience (2015)
418. The Evaluation of Multiple Sclerosis Dispersal in Iran and Its Association With Urbanization, Life Style and Industry, Iranian Journal of Public Health (2015)
419. The Role of Cerebellar Abnormalities in Neuromyelitis Optica - a Comparison With Multiple Sclerosis and Healthy Controls, Multiple Sclerosis (2015)
420. The Role of the Cerebellum in Multiple Sclerosis, Cerebellum (2015)
421. Translation, Cultural Adaptation and Validation of the Qualiveen-30 Questionnaire in Persian for Patients With Spinal Cord Injury and Multiple Sclerosis, LUTS: Lower Urinary Tract Symptoms (2015)
422. Two Functional Promoter Polymorphisms of Neuregulin 1 Gene Are Associated With Progressive Forms of Multiple Sclerosis, Journal of the Neurological Sciences (2015)
423. Does Lipoic Acid Consumption Affect the Cytokine Profile in Multiple Sclerosis Patients: A Double-Blind, Placebo-Controlled, Randomized Clinical Trial, NeuroImmunoModulation (2014)
424. Estimated Prevalence and Incidence of Multiple Sclerosis in Iran, European Neurology (2014)
425. Islamic Fasting and Multiple Sclerosis, BMC Neurology (2014)
426. Multiple Sclerosis in Sistan and Baloochestan, South East Iran, Clinical Neurology and Neurosurgery (2013)
427. Is the Iranian Revolution to Blame for the Increasing Incidence of Multiple Sclerosis in Iran?, Neuroepidemiology (2012)
428. Female Hormones and Multiple Sclerosis, Women and Multiple Sclerosis (2010)
429. Multiple Sclerosis and Neurofibromatosis Type 1: Report of Seven Patients From Iran, Multiple Sclerosis (2009)